Kees Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kees Boer has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
C Tempelman
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publicationsM H Godfried
2 shared publicationsS Timmermans
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications- Catharina P. B. van der Ploeg
Department of Child Health, TNO, Leiden, The Netherlands
1 shared publication - Colette Smit
HIV Monitoring Foundation, Tafelbergweg 51, 1105, BD, Amsterdam, the Netherlands
1 shared publication D Patel
Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 30 June 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 185
Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective
A screening programme for pregnant women has been in place since the 1950s in the Netherlands. In 2004 universal HIV screening according to opting out was implemented. Here, we describe the evaluation of the effectiveness of antenatal screening in the Netherlands for 2006-2008 for HIV, hepatitis B virus (HBV) and syphilis in preventing mother-to-child transmission, by using various data sources.
- 30 June 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 185
Open AccessAntenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective
A screening programme for pregnant women has been in place since the 1950s in the Netherlands. In 2004 universal HIV screening according to opting out was implemented. Here, we describe the evaluation of the effectiveness of antenatal screening in the Netherlands for 2006-2008 for HIV, hepatitis B virus (HBV) and syphilis in preventing mother-to-child transmission, by using various data sources.
- Open Access
- 9 January 2007
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 114 (2) , 148-155
The AmRo study: pregnancy outcome in HIV‐1‐infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery
Objective To explore pregnancy outcome in HIV‐1‐positive and HIV‐negative women, and mother‐to‐child transmission (MTCT) according to mode of delivery under effective highly active antiretroviral therapy (HAART).Design Cohort of 143 pregnant HIV‐1‐infected women including a matched case–control study in a 2:1 ratio of controls to cases (n = 98).Setting Academic Medical Center in Amsterdam and Erasmus Medical Center in Rotterdam, the Netherlands.Population Consecutive referred HIV‐1 infected pregnant women treated with HAART and matched control not infected pregnant women.Main outcome measures MTCT, preterm delivery, low birthweight, pre‐eclampsia.Results MTCT was 0% (95% CI 0–2.1%). Seventy‐eight percent of HIV‐1‐infected women commenced and 62% completed vaginal delivery. The calculated number of caesarean sections needed to prevent a single MTCT was 131 or more. Preterm delivery rates were 18% (95% CI 11–27) in women infected with HIV‐1 and 9% (95% CI 5–13) in controls (P = 0.03). HAART used at Conclusions We have not demonstrated any MTCT after vaginal delivery in women effectively treated by HAART. The HAART‐associated increase in preterm delivery rate is mainly seen after first trimester HAART use.
- 9 January 2007
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 114 (2) , 148-155
Open AccessThe AmRo study: pregnancy outcome in HIV‐1‐infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery
Objective To explore pregnancy outcome in HIV‐1‐positive and HIV‐negative women, and mother‐to‐child transmission (MTCT) according to mode of delivery under effective highly active antiretroviral therapy (HAART).Design Cohort of 143 pregnant HIV‐1‐infected women including a matched case–control study in a 2:1 ratio of controls to cases (n = 98).Setting Academic Medical Center in Amsterdam and Erasmus Medical Center in Rotterdam, the Netherlands.Population Consecutive referred HIV‐1 infected pregnant women treated with HAART and matched control not infected pregnant women.Main outcome measures MTCT, preterm delivery, low birthweight, pre‐eclampsia.Results MTCT was 0% (95% CI 0–2.1%). Seventy‐eight percent of HIV‐1‐infected women commenced and 62% completed vaginal delivery. The calculated number of caesarean sections needed to prevent a single MTCT was 131 or more. Preterm delivery rates were 18% (95% CI 11–27) in women infected with HIV‐1 and 9% (95% CI 5–13) in controls (P = 0.03). HAART used at Conclusions We have not demonstrated any MTCT after vaginal delivery in women effectively treated by HAART. The HAART‐associated increase in preterm delivery rate is mainly seen after first trimester HAART use.
- 9 October 2004
- Vol. 148 (41) , 2021-5
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
To assess the side effects, safety and efficacy of highly active antiretroviral therapy (HAART) in a cohort of HIV-infected pregnant women in the Netherlands. Retrospective. Data were collected from the medical records of HIV-infected pregnant women who received HAART during pregnancy in the period 1 January 1997-1 June 2003 at 14 HIV-specialized centres in the Netherlands. The inclusion criteria were at least a triple drug regimen and birth at 20 or more weeks of gestation. Information was collected about patient characteristics, HAART prescribed, side effects, viral load response, mode of delivery and HIV-status of the neonate. A total of 267/413 women satisfied the inclusion criteria. Most women (n = 199) had not previously received anti-retroviral therapy and started HAART between weeks 21 and 28 of the pregnancy. The two most frequently used regimens contained nelfinavir (57%) or nevirapine (31%). Gastrointestinal side effects were more frequently observed in the nelfinavir group, while rash and hepatotoxicity were more frequently reported in the nevirapine group. Efficacy and pregnancy outcome were similar in both groups. Two infants (0.7%) were HIV-infected. HAART regimens containing nelfinavir or nevirapine in HIV-infected pregnant women were safe, effective and well tolerated.
- 9 October 2004
- Vol. 148 (41) , 2021-5
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
To assess the side effects, safety and efficacy of highly active antiretroviral therapy (HAART) in a cohort of HIV-infected pregnant women in the Netherlands. Retrospective. Data were collected from the medical records of HIV-infected pregnant women who received HAART during pregnancy in the period 1 January 1997-1 June 2003 at 14 HIV-specialized centres in the Netherlands. The inclusion criteria were at least a triple drug regimen and birth at 20 or more weeks of gestation. Information was collected about patient characteristics, HAART prescribed, side effects, viral load response, mode of delivery and HIV-status of the neonate. A total of 267/413 women satisfied the inclusion criteria. Most women (n = 199) had not previously received anti-retroviral therapy and started HAART between weeks 21 and 28 of the pregnancy. The two most frequently used regimens contained nelfinavir (57%) or nevirapine (31%). Gastrointestinal side effects were more frequently observed in the nelfinavir group, while rash and hepatotoxicity were more frequently reported in the nevirapine group. Efficacy and pregnancy outcome were similar in both groups. Two infants (0.7%) were HIV-infected. HAART regimens containing nelfinavir or nevirapine in HIV-infected pregnant women were safe, effective and well tolerated.